Biothera unveils updated data from Phase 2 mTNBC trial at SABCS
Category: #health  By Mateen Dalal  Date: 2019-12-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biothera unveils updated data from Phase 2 mTNBC trial at SABCS

Biothera Pharmaceuticals, Inc., a renowned Minnesota based biotechnology company, reportedly announced that clinical benefit data and updated response from its Phase 2 study in chemo-refractory mTNBC (metastatic triple negative breast cancer) patients would be presented in a Spotlight Session during the 2019 San Antonio Breast Cancer Symposium (SABCS).

The Phase 2 study evaluates Biothera’s Imprime PGG, which is a systematically delivered dectin receptor triggering anti-cancer immune responses, with the anti-PD-1 therapy developed by Merck, KEYTRUDA® (pembrolizumab). The participants of the study were not treated earlier using immune checkpoint inhibitors. They also were identified as positive biomarker for Imprime PGG therapy.

Jeremy Graff, Ph.D., President and Chief Scientific Officer, Biothera Pharmaceuticals, reportedly stated that the clinical data showed compelling evidence from the combination of KEYTRUDA and Imprime PGG in chemo refractory mTNBC patients. Graff further added that the translational data not just delivers proof of concept at the cellular and molecular level, but also offers valuable insights regarding the next steps for clinical development of Imprime PGG.

Latest data from IMPRIME 1 showcased at SABCS depicted 15.9% overall response rate in mTNBC patients that were treated with the combination of KEYTRUDA and Imprime PGG.

Most of the patients showed target lesion stabilization or reduction. The discontinuation of treatment frequently resulted from increase in non-target lesion or new lesions, even when target lesions were stable or shrinking. Patients with such mixed response pattern showed an overall increase in survival.
 

About Biothera Pharmaceuticals:

Biothera Pharmaceuticals is a renowned biotechnology company headquartered in Minnesota. The firm is committed in developing CPIs, or immune checkpoint inhibitors in combination with Imprime PGG in multiple Phase 2 cancer indications. Its focus is on population of patients and types of tumor wherein single agent CPI therapy provides limited benefits. The types of tumor include non-small cell lung cancer, metastatic triple negative breast cancer, CPI-failed advanced melanoma and colorectal cancer.

 

Source credit: https://www.biothera.com/biothera-pharmaceuticals-presents-updated-phase-2-data-for-chemo-refractory-triple-negative-breast-cancer-patients-at-san-antonio-breast-cancer-symposium/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...